Nurix Therapeutics, Inc.
NRIXNurix Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery and development of targeted protein degradation medicines for cancer and inflammatory diseases.
Earnings
Next report
Oct 8, 2026 (in 2 months)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Nurix Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery and development of targeted protein degradation medicines for cancer and inflammatory diseases. The company utilizes a proprietary AI-integrated discovery engine and E3 ligase expertise to create small molecules and degrader antibody conjugates that modulate protein levels. Their platform aims to address previously undruggable targets by leveraging DNA-encoded libraries and machine learning to accelerate drug design.
A leader in the targeted protein degradation space with a specialized AI-driven DNA-encoded library (DEL) platform and a robust pipeline of first-in-class candidates.
FAQ
- What is Nurix Therapeutics, Inc.'s market cap?
- Nurix Therapeutics, Inc. (NRIX) has a market capitalization of $2.4B and trades on NASDAQ.
- What is Nurix Therapeutics, Inc.'s revenue and profitability?
- Nurix Therapeutics, Inc. generated $36.8M in trailing twelve-month revenue with a net loss of $341.4M, representing a net margin of -928.4%, with free cash flow of -$304.5M. These figures are based on the Q2 2026 filing.
- Who are Nurix Therapeutics, Inc.'s competitors?
- Nurix Therapeutics, Inc.'s key competitors include Arvinas, Inc., Kymera Therapeutics, Inc., C4 Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
- Who does Nurix Therapeutics, Inc. partner with?
- Nurix Therapeutics, Inc.'s notable partners include Gilead Sciences, Inc., Sanofi S.A., Pfizer Inc..
- Where is Nurix Therapeutics, Inc. headquartered?
- Nurix Therapeutics, Inc. is headquartered in United States of America and employs approximately 284 people. It has been publicly traded since 2020.
